Valérie Taupin, Teoxane CEO
January 6, 2025 03:31 PM EST
Deals

Teox­ane is­sues com­pet­ing buy­out bid for Re­vance and its Botox ri­val

Nicole DeFeudis

Editor

Re­vance Ther­a­peu­tics’ con­tract dis­pute with a Swiss part­ner has caused hic­cups in its plan to be ac­quired by Crown Lab­o­ra­to­ries. Now that part­ner says it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Aet­na takes Take­da to court over 'an­ti­com­pet­i­tive scheme' with gener­ic drugs

A service from the Financial Times